当前位置：首页 SCI 期刊医学 Clinical Drug Investigation(非官网)

Clinical Drug InvestigationSCIE

国际简称：CLIN DRUG INVEST 参考译名：临床药物调查

中科院分区
3区
CiteScore分区
Q2
JCR分区
Q2

基本信息：: ISSN：1173-2563; E-ISSN：1179-1918; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：NEW ZEALAND; 出版商：Springer International Publishing; 出版语言：English; 出版周期：Monthly; 出版年份：1989; 研究方向：医学-药学

评价信息：: 影响因子：2.9; H-index：53; CiteScore指数：5.9; SJR指数：0.68; SNIP指数：0.798

发文数据：: Gold OA文章占比：44.96%; 研究类文章占比：76.47%; 年发文量：85; 自引率：0.0312...; 开源占比：0.3934; 出版撤稿占比：0; 出版国人文章占比：0.1; OA被引用占比：0.2146...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Clinical Drug Investigation期刊介绍

Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes:

-Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs.

-Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice.

-Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed.

-Studies focusing on the application of drug delivery technology in healthcare.

-Short communications and case study reports that meet the above criteria will also be considered.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.

期刊简介Clinical Drug Investigation期刊介绍

《Clinical Drug Investigation》自1989出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：较慢,6-12周
医学
PHARMACOLOGY & PHARMACY
SCIE
中科院3区
非预警

Cite Score数据（2024年最新版）Clinical Drug Investigation Cite Score数据

CiteScore：5.9
SJR：0.68
SNIP：0.798

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q2	81 / 272	70%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Clinical Drug Investigation 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	3区	PHARMACOLOGY & PHARMACY 药学	3区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Clinical Drug Investigation JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	147 / 354	58.6%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	125 / 354	64.83%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA90
Japan56
CHINA MAINLAND51
Italy48
England37
Spain25
New Zealand23
South Korea17
Canada16
GERMANY (FED REP GER)16

本刊中国学者近年发表论文

1、Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment
Author: Liu, Xinyu; Shi, Jian; Wang, Deyang; Su, Ying; Xing, Zhen; Sun, Fei; Chen, Fei

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. 43, Issue 1, pp. 13-22. DOI: 10.1007/s40261-022-01231-w
2、Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis
Author: Gao, Mengxia; Zhu, Lingqun; Chang, Jingling; Cao, Tianyu; Song, Lianying; Wen, Chunli; Chen, Yi; Zhuo, Yudi; Chen, Fei

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. 43, Issue 1, pp. 1-11. DOI: 10.1007/s40261-022-01229-4
3、Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women
Author: Shao, Feng; Jiang, Yi; Ding, Sijia; Larsson, Per; Pinton, Philippe; Jonker, Daniel Martijn

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. 43, Issue 1, pp. 37-44. DOI: 10.1007/s40261-022-01232-9
4、A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study
Author: Deng, Haiyi; Deng, Jiating; Lin, Xinqing; Guan, Wenhui; Lin, Ziying; Qiu, Yanli; Yang, Yilin; Wu, Jianhui; Qiu, Guihuan; Sun, Ni; Zhou, Maolin; Deng, Jiaxi; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Qin, Yinyin; Zhou, Yanbin; Zhou, Chengzhi

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40261-023-01267-6
5、A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects
Author: Jing, Shan; Shiba, Sari; Morita, Masafumi; Yasuda, Sanae; Lin, Yang

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. 43, Issue 3, pp. 155-165. DOI: 10.1007/s40261-022-01241-8
6、Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
Author: Zhang, Senlin; Wang, Qingwei; Cui, Kai; Cheng, Bingjie; Fan, Junjie; Hu, Shaoyan

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40261-023-01266-7
7、Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers
Author: Yu, Xiangyou; Hao, Yan; Zhu, Zhanfang; Zhang, Wei; Liu, Bo; Ma, Meijuan; Zhang, Xuejun; Wei, Na; Wang, Junkui; Liu, Fuqiang

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40261-023-01253-y
8、A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China
Author: Jiang, Yanqing; Liu, Ruizhe; Xuan, Jianwei; Lin, Sisi; Zheng, Qiang; Pang, Jianxin

Journal: CLINICAL DRUG INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40261-023-01255-w